LATTICE MEDICAL secures €3.6 million in funding!

Lille, 26 September 2024 – LATTICE MEDICAL, which has been awarded the FrenchTech 2030 label, is proud to announce that it has received €3.6 million in funding for the M3DINPRINT project, as part of the Health 2030 Capacity Programme.

The M3DINPRINT project aims to develop an innovative production tool that is unique in the world, the first clean-room 3D printing farm capable of producing large volumes of LATTICE MEDICAL’s innovative devices such as MATTISSE for breast reconstruction and RODIN for hypodermal reconstruction.

LATTICE MEDICAL will also develop a Contract Development & Manufacturing activity on behalf of its customers via its LATTICE SERVICES business.

The final objective of the project is the regulatory validation of our future factory to enable us to roll out the manufacture of thousands of 3D printed implants adapted to patients.

This significant funding marks a crucial step forward in our project. Lattice Medical would like to express its gratitude to all the stakeholders in the France 2030 programme, the SGPI (Secrétariat Général Pour l’Investissement), the AIS (Agence Innovation Santé), BPIFrance and the FrenchTech teams.

LATTICE MEDICAL is a French Medtech company with 25 employees and FrenchTech2030 accreditation, which aims to provide patients and healthcare professionals with personalised tissue reconstruction solutions using a combination of biomaterials, tissue engineering and 3D printing technologies.

The first technology developed by the company is the MATTISSE bioprosthesis. This flagship product, currently under clinical investigation in Europe, is a resorbable tissue engineering chamber that will enable a more natural and simplified breast reconstruction for women who have had breast cancer.

Click here to download the press release.

Press contact:

Emma Legname / presse@lattice-medical.com / 09 73 79 84 12